The World Health Organization (WHO) reports that:
- 2.3 million people living with HIV in the WHO European Region have been infected with the virus over the past 40 years
- In 2021, nearly 80 percent of all deaths were due to malaria in the WHO African Region
These numbers indicate that HIV/AIDS and malaria remain major public health problems worldwide.
In this webinar, attendees will learn about the strategic potential of humanized mice in the search for treatments for these infections.
In the first part, featured speaker Dr. Sebastien Tabruyn, will discuss how the human immune system responds to infection in a humanized CD34-NCG mouse model, the preclinical analysis toolkit of the HIV platform and how the humanized model allows for the evaluation of drug candidates, especially for infectious diseases.
In the second part, featured speaker Dr. Iñigo Angulo-Barturen, will discuss the humanized Plasmodium falciparum mouse model for the study of human malaria and in vivo evaluation of new antimalarial drugs. He will present the characteristics of the humanized P. falciparum asexual blood stage (ABS) mouse models available at the drug discovery company TAD, their use as tools to study the development of resistance during suboptimal treatment regimens and the efficacy of monoclonal antibodies and drugs against susceptible and resistant strains.
Register today to find out how humanized mice models can accelerate preclinical studies in infectious diseases such as malaria and HIV.
Dr. Sebastien Tabruyn, PhD CSO, TransCure bioServices
Chief Scientific Officer and General Manager, Sebastien Tabruyn holds a PhD in molecular biology from the University of Liege (Belgium). After 20 years of experience as project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 to develop the first IO humanized mouse models. Sebastien Tabruyn published more than 30 peer-reviewed publications mostly focused on oncology, inflammation, immunity and angiogenesis.
Iñigo Angulo-Barturen, PhD, CEO, The Art of Discovery SL
Dr. Iñigo Angulo-Barturen has a degree in biology from the University of the Basque Country (Leioa, Spain), a PhD in immunology from the Universidad Complutense (Madrid, Spain) and is a Specialist in Immunology (residency at Hospital Universitario San Carlos, Madrid, Spain). After a postdoctoral period developing new immunotherapies for fungal infections in immunodepressed patients (Centro de Biología Molecular, Cantoblanco, Spain and GlaxoWellcome, Tres Cantos, Madrid), he led the preclinical Therapeutic Efficacy Group at GlaxoSmithKline, Tres Cantos, Spain), conducting the evaluation of new medicines in drug discovery programs for malaria and tuberculosis. At GSK, Dr. Angulo-Barturen developed the first industrial murine model of P. falciparum human malaria that became the gold standard in drug discovery for translational research in programs supported by the Medicines for Malaria Venture. In 2015, Dr. Angulo-Barturen founded The Art of Discovery (TAD), a company specialized in translational evaluation of new drugs in humanized mouse models of key human diseases.
Who Should Attend?
- Pharma Project Management
- Outsourcing Manager
- Scientific Researchers
- Members of Academic Institutions
- Pharmacology Lead
- Drug Discovery Scientist
What You Will Learn
Attendees will gain insights into:
- The main characteristics, the equipment used and advantages of a mouse model with a complete human immune system
- Benefits of incorporating this model into preclinical trials for potential HIV drug or vaccine targets
- The characteristics of the humanized P. falciparum mouse model that can help research projects
- The level of standardization, reproducibility, accumulated knowledge and operational execution of the model as well as the ease of integration with research resources
TransCure bioServices offers pre-clinical contract research services to pharmaceutical, biotech, start-up and academic researchers who need faster, smarter and cost-effective solutions for drug profiling. Uniquely designed mouse modeling with functional humanized systems have been developed to provide predictive in vivo pharmacology testing in the field of immuno-oncology, inflammation, autoimmune diseases, infectious diseases and vaccine development. With an unparalleled expertise, powerful humanized mouse models, short lead times, and flexibility, they support their clients from study design to final report.